Hepatitis C pharmacogenetics: State of the art in 2010

Nezam H. Afdhal; John G. McHutchison; Stefan Zeuzem; Alessandra Mangia; Jean Michel Pawlotsky; Jeffrey S. Murray; Kevin V. Shianna; Yasuhito Tanaka; David L. Thomas; David R. Booth; David B. Goldstein

doi:10.1002/hep.24052

Hepatitis C pharmacogenetics: State of the art in 2010

Nezam H. Afdhal, John G. McHutchison, Stefan Zeuzem, Alessandra Mangia, Jean Michel Pawlotsky, Jeffrey S. Murray, Kevin V. Shianna, Yasuhito Tanaka, David L. Thomas, David R. Booth, David B. Goldstein

School of Medicine

Research output: Contribution to journal › Article › peer-review

130 Scopus citations

Abstract

In 2009, a correlated set of polymorphisms in the region of the interleukin-28B (IL28B) gene were associated with clearance of genotype 1 hepatitis C virus (HCV) in patients treated with pegylated interferon-alfa and ribavirin. The same polymorphisms were subsequently associated with spontaneous clearance of HCV in untreated patients. The link between IL28B genotype and HCV clearance may impact decisions regarding initiation of current therapy, the design and interpretation of clinical studies, the economics of treatment, and the process of regulatory approval for new anti-HCV therapeutic agents.

Original language	English (US)
Pages (from-to)	336-345
Number of pages	10
Journal	Hepatology
Volume	53
Issue number	1
DOIs	https://doi.org/10.1002/hep.24052
State	Published - Jan 2011

ASJC Scopus subject areas

Hepatology

Access to Document

10.1002/hep.24052

Cite this

@article{83f1e753c63544e7b4ee56368199de6a,

title = "Hepatitis C pharmacogenetics: State of the art in 2010",

abstract = "In 2009, a correlated set of polymorphisms in the region of the interleukin-28B (IL28B) gene were associated with clearance of genotype 1 hepatitis C virus (HCV) in patients treated with pegylated interferon-alfa and ribavirin. The same polymorphisms were subsequently associated with spontaneous clearance of HCV in untreated patients. The link between IL28B genotype and HCV clearance may impact decisions regarding initiation of current therapy, the design and interpretation of clinical studies, the economics of treatment, and the process of regulatory approval for new anti-HCV therapeutic agents.",

author = "Afdhal, {Nezam H.} and McHutchison, {John G.} and Stefan Zeuzem and Alessandra Mangia and Pawlotsky, {Jean Michel} and Murray, {Jeffrey S.} and Shianna, {Kevin V.} and Yasuhito Tanaka and Thomas, {David L.} and Booth, {David R.} and Goldstein, {David B.}",

year = "2011",

month = jan,

doi = "10.1002/hep.24052",

language = "English (US)",

volume = "53",

pages = "336--345",

journal = "Hepatology",

issn = "0270-9139",

publisher = "John Wiley and Sons Ltd",

number = "1",

}

TY - JOUR

T1 - Hepatitis C pharmacogenetics

T2 - State of the art in 2010

AU - Afdhal, Nezam H.

AU - McHutchison, John G.

AU - Zeuzem, Stefan

AU - Mangia, Alessandra

AU - Pawlotsky, Jean Michel

AU - Murray, Jeffrey S.

AU - Shianna, Kevin V.

AU - Tanaka, Yasuhito

AU - Thomas, David L.

AU - Booth, David R.

AU - Goldstein, David B.

PY - 2011/1

Y1 - 2011/1

N2 - In 2009, a correlated set of polymorphisms in the region of the interleukin-28B (IL28B) gene were associated with clearance of genotype 1 hepatitis C virus (HCV) in patients treated with pegylated interferon-alfa and ribavirin. The same polymorphisms were subsequently associated with spontaneous clearance of HCV in untreated patients. The link between IL28B genotype and HCV clearance may impact decisions regarding initiation of current therapy, the design and interpretation of clinical studies, the economics of treatment, and the process of regulatory approval for new anti-HCV therapeutic agents.

AB - In 2009, a correlated set of polymorphisms in the region of the interleukin-28B (IL28B) gene were associated with clearance of genotype 1 hepatitis C virus (HCV) in patients treated with pegylated interferon-alfa and ribavirin. The same polymorphisms were subsequently associated with spontaneous clearance of HCV in untreated patients. The link between IL28B genotype and HCV clearance may impact decisions regarding initiation of current therapy, the design and interpretation of clinical studies, the economics of treatment, and the process of regulatory approval for new anti-HCV therapeutic agents.

UR - http://www.scopus.com/inward/record.url?scp=78751508078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78751508078&partnerID=8YFLogxK

U2 - 10.1002/hep.24052

DO - 10.1002/hep.24052

M3 - Article

C2 - 21254181

AN - SCOPUS:78751508078

SN - 0270-9139

VL - 53

SP - 336

EP - 345

JO - Hepatology

JF - Hepatology

IS - 1

ER -

Hepatitis C pharmacogenetics: State of the art in 2010

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this